Cargando…
“True” Antiandrogens—Selective Non-Ligand-Binding Pocket Disruptors of Androgen Receptor–Coactivator Interactions: Novel Tools for Prostate Cancer
[Image: see text] Prostate cancer (PCa) therapy typically involves administration of “classical” antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Pr...
Autores principales: | Caboni, Laura, Kinsella, Gemma K., Blanco, Fernando, Fayne, Darren, Jagoe, William N., Carr, Miriam, Williams, D. Clive, Meegan, Mary J., Lloyd, David G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2012
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295204/ https://www.ncbi.nlm.nih.gov/pubmed/22280402 http://dx.doi.org/10.1021/jm201438f |
Ejemplares similares
-
Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen
por: Takeda, Keisuke, et al.
Publicado: (2016) -
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
por: Tian, Xiaohong, et al.
Publicado: (2015) -
Corrigendum: Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance
por: Tian, Xiaohong, et al.
Publicado: (2015) -
Cyclin E as a Coactivator of the Androgen Receptor
por: Yamamoto, Ayako, et al.
Publicado: (2000) -
Androgens and environmental antiandrogens affect reproductive development and play behavior in the Sprague-Dawley rat.
por: Hotchkiss, A K, et al.
Publicado: (2002)